Postoperative landiolol plus oral beta-blocker to prevent new-onset atrial fibrillation after cardiac surgery

Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Landiolol plus oral beta-blocker with Placebo plus oral beta-blocker (2 arms). Primary endpoint: First episode of postoperative atrial fibrillation within 7 postoperative days. Planned start Oct 2026; status: authorised.